Specify a stock or a cryptocurrency in the search bar to get a summary
Bone Biologics Corp
BBLGBone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Address: 2 Burlington Woods Drive, Burlington, MA, United States, 01803
Analytics
WallStreet Target Price
16.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BBLG
Dividend Analytics BBLG
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BBLG
Stock Valuation BBLG
Financials BBLG
Results | 2019 | Dynamics |